A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

NCT07720375 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions

BIOLOGICAL: Galvokimig
BIOLOGICAL: Placebo

Sponsor

UCB Biopharma SRL